The National Institutes of Health’s Post

A Phase 1 trial testing the safety of an experimental nasal vaccine that may provide enhanced breadth of protection against emerging variants of SARS-CoV-2, the virus that causes COVID-19, is now enrolling healthy adults at three sites in the United States. Read more: https://bit.ly/45MTDqg #COVID19 #COVID19vaccine #research #science #NIH

NIH-sponsored trial of nasal COVID-19 vaccine opens

NIH-sponsored trial of nasal COVID-19 vaccine opens

nih.gov

Exciting to see a Phase 1 trial for an experimental nasal vaccine against SARS-CoV-2 variants! At Fast Data Science, our Clinical Trial Risk Tool uses natural language processing to categorise trial protocols as high, medium, or low risk of ending uninformatively. This helps streamline the assessment process, ensuring thorough evaluation before trials begin. 👉 Try it here for Free: https://clinicaltrialrisk.org/ The tool allows you to upload a trial protocol and quickly assess key factors such as trial duration, participant risk, and treatment type. Best of all, it’s open-source under the MIT licence and doesn’t save any of your data. Learn more about how we can support your clinical trial needs.

Like
Reply

To view or add a comment, sign in

Explore topics